PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.82%
R&D growth while TRVN reduces spending. John Neff would investigate strategic advantage.
-13.19%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
Other expenses reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine efficiency.
-2.45%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-2.45%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
D&A reduction while TRVN shows 27.54% growth. Joel Greenblatt would examine efficiency.
-13.13%
EBITDA decline while TRVN shows 14.90% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
2.45%
Operating income growth below 50% of TRVN's 14.78%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
49.45%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
10.71%
Pre-tax income growth 50-75% of TRVN's 14.41%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.71%
Net income growth 50-75% of TRVN's 14.41%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
23.59%
EPS growth 50-75% of TRVN's 42.50%. Martin Whitman would scrutinize operations.
23.59%
Diluted EPS growth 50-75% of TRVN's 42.50%. Martin Whitman would scrutinize operations.
16.70%
Share count reduction exceeding 1.5x TRVN's 48.87%. David Dodd would verify capital allocation.
16.70%
Diluted share reduction exceeding 1.5x TRVN's 48.87%. David Dodd would verify capital allocation.